MICHAEL BALDWIN: Open Payments
NPI 1780618371 · DEARBORN, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,941 in 94 payments from 32 companies in 2025. Trend: 2023 $2,034 · 2024 $2,070 · 2025 $2,941
Food & beverage: $2,941
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $588 |
| Novo Nordisk Inc | 9 | $351 |
| ABBVIE INC. | 8 | $233 |
| Axsome Therapeutics, Inc. | 4 | $229 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $201 |
| Braeburn Inc. | 2 | $144 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Aimmune Therapeutics, Inc. | 4 | $112 |
| PFIZER INC. | 6 | $103 |
| Exact Sciences Corporation | 5 | $95 |
Products named: AIRSUPRA, BREZTRI, Auvelity, CAPLYTA, VRAYLAR, BRIXADI, Wegovy, REXULTI.
Industry payments across MI — which companies pay providers there.
